Full Text

• Feuerstein G, Hallenbeck JM: Prostaglandins, leukotrienes and platelet activating factor in shock. Annu Rev Pharmacol Toxicol 1987; 27:301-313
• Braquet P, Paubert-Braquet M, Bourgain RH, et al: Platelet-activating factor/cytokines autoregulated feedback networks in microvascular injury: Consequences in shock, ischemia and graft rejection. J Lipid Med 1989; 1:75-112
• Myers AK, Robey JW, Price RM: Relationships between tumor necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol 1990; 99:499-502
• Serhan CN, Haeggström JZ, Leslie CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FASEB J 1996; 10:1147-1158
• Bussolino F, Porcellini MG, Varese L, et al: Intravascular release of platelet activating factor in children in sepsis. Thromb Res 1987; 48:619-620
• Diez FL, Nieto M, Fernandez-Gallardo S, et al: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83:1733-1740
• Leaver HA, Qu JM, Smith G, et al: Endotoxin releases platelet-activating factor from human monocytes in vitro. Immunopharmacology 1990; 20: 105-113
• Cabellos C, MacIntyre DE, Forrest M, et al: Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae. J Clin Invest 1992; 90: 612-618
• Graham RM, Stephens CJ, Silvester W, et al: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22:204-212
• Saunders RN, Handley DA: Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol 1987; 27:237-255
• Koltai M, Osford D, Guinot P, et al: Platelet activating factor. A review of its effects, antagonists and possible future clinical applications (Part I). Drugs 1991; 42:9-29
• Koltai M, Osford D, Guinot P, et al: Platelet activating factor. A review of its effects, antagonists and possible future clinical applications (Part II). Drugs 1991; 42:174-204
• Dhainaut JF, Mira JP, Brunet F: Platelet-activating factor antagonists as therapeutic strategy in sepsis. In: Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies. Levin J, van Deventer SJH, van der Poll T, et al (Eds). New York, Wiley-Liss, 1994, pp 277-293
• Etienne A, Hecquet F, Soulard C, et al: In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific platelet-activating factor-acether antagonist: BN 52021. Agents Actions 1985; 17:368-370
• Adnot S, Lefort J, Lagente V, et al: Interference of BN 52021, a platelet-activating factor-acether antagonist, with endotoxin-induced hypotension in the guinea-pig. Pharmacol Res Commun 1986; 18:197-200
• Etienne A, Hecquet F, Soulard C, et al: Inhibition of rat endotoxin-induced lethality by BN 52021 and BN 52063, compounds with platelet-activating factor-acether antagonistic effect and protease-inhibitory activity. Int J Tissue React 1987; 9:19-26
• Rabinovici R, Yue TL, Farhat M, et al: Platelet-activating factor and TNF interactions in endotoxemic shock: Studies with BN 50739, a novel platelet-activating factor antagonist. J Pharmacol Exp Ther 1990; 255: 258-263
• Feuerstein G, Leader P, Siren AL, et al: Protective effect of a platelet-activating factor-acether antagonist, BN 52021, in trichothecene toxicosis. Toxicol Lett 1987; 38:271-274
• Duchier J, Cournot A, Hosford D, et al: Clinical studies on the tolerance and effects of BN 52021 on PAF-induced platelet aggregation and skin reactivity in healthy volunteers. In: Ginkgolides-Chemistry, Biology, Pharmacology, and Clinical Perspectives. Vol 2. Braquet P (Ed). Barcelona, Spain, Prous Science Publishers, 1989, pp 897-904
• Nathan N, Mercury P, Denizot Y, et al: Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopulmonary bypass. Anesth Analg 1994; 79:205-211
• Grino JM for the BN 52021 study group in renal transplantation: BN 52021, a platelet-activating factor antagonist, to prevent post-transplant renal failure. Ann Intern Med 1994; 121:345-347
• Brocher B, Guinot P, Orgogozo JM, et al: Double blind placebo controlled multicentre study of ginkgolide B on treatment of acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 58:360-362
• Dhainaut JFA, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1995; 22:1720-1728
• Björk L, Andersson J, Ceska M, et al: Endotoxin and Staphylococcus aureus enterotoxin-A induce different patterns of cytokines. Cytokine 1992; 4:513-519
• Fisher CJ, Dhainaut JFA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist reduces the mortality of patients with septic syndrome as a function of disease severity: A randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-1843
• American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
• Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17: 389-393
• Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiologic score (SAPS II) based on a European-North American multicenter study. JAMA 1993; 270:2957-2963
• McCabe WR, Jackson GG: Gram negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110: 845-855
• Murray JF, Matthay MA, Luce JM, et al: An expanded definition of the ARDS. Am Rev Respir Dis 1988; 138:720-723
• Wenzel RP: Anti-endotoxin monoclonal antibodies - A second look. N Engl J Med 1992; 326:1151-1153
• Cross AS: Anti-endotoxin antibodies: A dead end? Ann Intern Med 1994; 121:58-60
• Abraham E, Raffin TA: Sepsis therapy trials: Continued disappointment or reason for hope? JAMA 1994; 271: 1876-1878
• Opal SM: Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2:221-226
• Sibbald WJ, Vincent JL: Roundtable conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394-399
• Fink MP: Another negative clinical trial for a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatment for serious infections. Crit Care Med 1995; 223:989-991
• Milberg JA, Davis DR, Steinberg KP, et al: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306-309
• Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra-costs, and attributable mortality. JAMA 1994; 271:1596-1601
• Sprung CL, Eidelman LA, Pizov R, et al: Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial. Crit Care Med 1997; 25:383-387
• Cohen J, Carlet J, INTERSEPT Study Group: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24:1431-1440
• Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human TNF-α in patients with sepsis syndrome. JAMA 1995; 273:934-941
• Abraham E, Glauser MP, Butler T, et al: P55 TNF factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277:1531-1538
• Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912-918.
• Knaus WA, Sun X, Nystrom PO, et al: Evaluation of definition for sepsis. Chest 1992; 101:1656-1662
• Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. From the bench to the bedside: The future of sepsis research. Chest 1997; 111: 744-753